Cathie's Ark Logo
Ionis Pharmaceuticals Inc Logo

Combined Holdings of Ionis Pharmaceuticals (IONS) - Updated Daily

TherapeuticsGenomicsRNA Therapy
Date
Direction
Shares
Fund Weight
Fund
December 2, 2022
SELL105.577k0.188%ARKG
December 1, 2022
SELL17.815k0.0316%ARKG
November 2, 2022
SELL51.310k0.0972%ARKG
November 1, 2022
SELL65.329k0.1248%ARKG
October 31, 2022
SELL15.959k0.0297%ARKG

Key Statistics

⚖️Weighting🧢Market Cap
0.71%$5.04b
🏋️‍♀️Weight Rank Across All Funds🌏Country
28🇺🇸United States
💳ARK Estimated Cost Average🎫ARK Ownership Percent
$43.70 - ARKG
1.79%
Description
For more than 30 years, Ionis has been the leader in RNA-targeted therapy, pioneering new markets and changing standards of care with its novel antisense technology. Ionis currently has three marketed medicines and a premier late-stage pipeline highlighted by industry-leading neurological and cardiometabolic franchises. Its scientific innovation began and continues with the knowledge that sick people depend on it, which fuels its vision of becoming one of the most successful biotechnology companies.
Website
www.ionispharma.com

Other ETFs That Hold IONS

Ticker
NameWeight
ARKGARK Genomic Revolution ETF4.7%
XBISPDR® S&P Biotech ETF0.95%